Search results
BioNTech SE (NASDAQ:BNTX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Simply Wall St. via Yahoo Finance· 5 days agoInvestors in BioNTech SE (NASDAQ:BNTX) had a good week, as its shares rose 2.3% to close at US$90.88...
Earnings call: BioNTech targets oncology growth, plans new COVID vaccine By Investing.com
Investing.com· 6 days agoBioNTech SE (NASDAQ:BNTX), a biotechnology company, reported its first-quarter financial results for...
We Discuss Why BioNTech SE's (NASDAQ:BNTX) CEO Will Find It Hard To Get A Pay Rise From Shareholders...
Simply Wall St. via Yahoo Finance· 2 days agoKey Insights BioNTech will host its Annual General Meeting on 17th of May CEO Ugur Sahin's total...
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 7 days agoImage source: The Motley Fool. BioNTech Se (NASDAQ: BNTX) Q1 2024 Earnings Call May 06, 2024, 8:00 a.m. ET Contents: Prepared Remarks Questions and...
BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come
Investor's Business Daily· 6 days agoBioNTech stock seesawed before closing in the green on Monday following a disappointing...
What's Going With BioNTech Stock On Monday?
Benzinga· 7 days agoMonday, BioNTech SE BNTX reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss...
BioNTech (NASDAQ:BNTX) PT Lowered to $122.00 at BMO Capital Markets
ETF DAILY NEWS· 3 days agoBioNTech (NASDAQ:BNTX – Free Report) had its price objective cut by BMO Capital Markets from $123.00 to $122.00 in a report released on Tuesday morning, Benzinga reports.
BioNTech shares hold rating, price target raised By Investing.com
Investing.com· 6 days agoTuesday, BioNTech SE (NASDAQ:BNTX) shares maintained their Hold rating, but with an updated price...
Will your last COVID vaccine work against new ‘FLiRT’ variants?
WJZY via Yahoo News· 16 hours agoUltimately, it depends on when you got your last dose. In fall, an updated COVID vaccine was...
UPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of year
Reuters via Yahoo Finance· 7 days agoGermany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would ...